Unterschiede

Hier werden die Unterschiede zwischen zwei Versionen angezeigt.

--- silybum_marianum_l._gaertn [2015/10/21 10:38] – andreas
+++ silybum_marianum_l._gaertn [2015/10/21 13:23] (aktuell) – andreas
@@ Zeile 15: / Zeile 15: @@
 "... silymarin appears to be effective to reduce the biochemical, inflammatory and ultrasonic indices of hepatic steatosis. Some parameters indicative of early stage of atherosclerosis were also lowered." \\
 [Silymarin in non alcoholic fatty liver disease., Cacciapuoti, F., Scognamiglio, A., Palumbo, R., Forte, R., Cacciapuoti, F., World journal of hepatology, 5(3), 2013, 109] [[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612568/]]
+"Silymarin is the entire extract containing seven flavonolignans and taxifolin. Silibinin is a mixture of silybin A and silybin B in a 1:1 ratio. The remaining flavonolignans are: isosilybin A, isosilybin B, silychristin, isosilychristin, and silydianin. The flavonoid found in silymarin is taxifolin... \\
+Presently, there is no clear evidence that any of the currently available over-the-counter preparations have efficacy in the treatment of liver disease. While there are compelling in vitro and animal data supporting the hepatoprotective effects of silymarin and inhibition of in vitro HCV infection, clinical data are equivocal, with some studies suggesting a protective effect of silymarin against progression of liver disease in subjects with hepatitis C, while other studies found no such effect. Thus, there is clinical controversy around whether silymarin and silymarin-derived compounds protect the liver." \\
+[Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection., Polyak, S. J., Ferenci, P., Pawlotsky, J.M., Hepatology, 57(3), 2013, 1262-1271] [[http://onlinelibrary.wiley.com/doi/10.1002/hep.26179/full]]
 {{:carduus_marianus.jpg?500}} \\